SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is seeing active discussion following reports regarding a partner's challenges in securing financing for a data center, a narrative largely countered by denials from the involved companies and speculation among traders about pre-earnings market manipulation.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is a focus of debate after its recent earnings showed massive ARR growth and its first positive adjusted EBITDA, yet some investors link its volatility to broader AI infrastructure funding challenges. Despite this, significant institutional accumulation and bullish analyst upgrades are driving a strong community conviction in its undervalued growth trajectory as a leading AI hyperscaler.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is highly volatile as the market digests the Supreme Court's ruling against tariffs and anticipates former President Trump's reaction, with the community divided on whether this signals reduced inflation and potential rate cuts or increased market uncertainty and new trade threats.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is actively trending amid discussions of its strategic investments in AI-enabled defense systems and new product unveilings, with the community highly anticipating a potential short squeeze driven by significant call options activity and broader sector momentum in drone dominance programs.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending following a Supreme Court ruling that struck down tariffs, challenging a core element of former President Trump's past economic policy and executive power. The community is widely debating the financial implications for consumers and businesses, including the prospect of significant tariff refunds, and the broader political repercussions.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike (NKE) is trending as the community expresses confusion over its recent sell-off, with many attributing the decline to market manipulation or a "sell the news" event, despite discussions around potential tariff relief and the company's restructuring efforts including layoffs. Investors are actively debating if NKE is a value trap or a prime opportunity for a long-term turnaround, especially given broader sector comparisons and concerns over its recent performance in key markets.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing significant volatility following the Supreme Court's decision to strike down President Trump's emergency tariffs, prompting a divided community discussion between bullish sentiment for potential lower inflation and rate cuts, and concerns over Trump's promised "backup plan" for tariffs and broader market uncertainty.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending upward after the FDA reversed its refusal and agreed to review the company's seasonal flu vaccine application, fueling a community-driven short squeeze. This regulatory pivot has invigorated bullish sentiment, with many anticipating continued gains driven by optimism for Moderna's oncology pipeline and AI-powered drug development.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is buzzing as it unveils its new Indensity battery architecture, a modular, high-density solution targeted at critical grid and data center power needs. Speculation is rampant within the community ahead of an imminent business update, with many investors anticipating significant partnerships or announcements that could leverage the company's safe, US-made, long-duration energy storage technology to address growing power demands.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL is trending following a steep market reaction to its NHS-Galleri trial missing its primary endpoint, though community discussion is divided with many seeing the sell-off as an overreaction given positive secondary detection data and continued analyst endorsements for the cancer early detection test.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by Brokerages

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have earned a consensus rating of "Hold" from the five ratings firms that are presently covering the firm, MarketBeat.com...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Sees Significant Increase in Short Interest

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 30th, there was short interest...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short...

OKYO Pharma (NASDAQ:OKYO) Trading Down 15.5% - What's Next?

OKYO Pharma (NASDAQ:OKYO) Shares Down 15.5% - Should You Sell...

OKYO Pharma CEO Gary Jacob Transitions To CDO; Appoints Robert Dempsey As CEO

(RTTNews) - OKYO Pharma Ltd. (OKYO), on Monday, said it has appointed Robert Dempsey as Chief Executive Officer, effective immediately...

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling...

OKYO Pharma (NASDAQ:OKYO) Stock Rating Upgraded by B. Riley

B. Riley raised OKYO Pharma to a "strong-buy" rating and set a $5.00 target price for the company in a research report on Monday...

OKYO Pharma (NASDAQ:OKYO) Shares Down 4.5% - Time to Sell?

OKYO Pharma (NASDAQ:OKYO) Shares Down 4.5% - Here's Why...

Shares of OKYO Pharma (OKYO) jumped 8% on Monday morning after the company said that it is now planning to advance to a multiple-ascending-dose (MAD) clinical trial for its lead drug candidate Urcosimod.Urcosimod is being developed to treat neuropathic corneal pain (NCP), a condition that causes severe pain and sensitivity of the eyes, face, or head, and is thought to result from nerve damage to the cornea combined with inflammation.In July, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://okyopharma.com/okyo-pharma-announces-registration-pathway-with-100-patient-multi-center-clinical-trial-of-urcosimod-in-neuropathic-corneal-pain/">announced</a> data from a mid-stage trial of Urcosimod in 17 NCP patients. After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% Urcosimod showed greater than 80% reduction in neuropathic corneal pain in that study, as measured by visual analog scale.Okyo said on Monday that it is now focused on advancing to a multiple-ascending-dose (MAD) clinical trial designed to enroll approximately 100 NCP patients across several U.S. clinical sites. The purpose of the trial is to identify the optimal registration dose for Urcosimod for future late-stage trials and to develop an understanding of the drug’s characteristics.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OKYO">OKYO stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_1_09_35_PM_png_4bfce5981c.webp" alt="OKYO's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Sept. 22, 2025 | Source: Stocktwits" width="578" height="57"><figcaption>OKYO's Sentiment Meter and Message Volume as of 1:09 p.m. ET on Sept. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that they now see a “clear route forward.”<stembedurl>https://stocktwits.com/rp6577/message/629485633</stembedurl>The company said that it expects data from this new trial in 2026, and negotiations are underway with several clinical sites in the U.S. Okyo continues to progress toward a meeting with the U.S. Food and Drug Administration (FDA) to discuss requirements for an approvable drug to treat NCP and to define the primary endpoint required for potential registration, it said.“Our next &nbsp;MAD clinical trial is designed to give us the data needed to define an optimal registration pathway for urcosimod, and we are moving rapidly to initiate this study. With Fast-Track designation in place and a constructive engagement anticipated with FDA, we are well-positioned to bring this novel therapy closer to patients in need,” said CEO Gary S Jacob.OKYO stock is up 85% this year and approximately 112% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-awarded-with-yet-another-price-target-hike-after-waymo-partnership/chDQu3aR32s">Lyft Awarded With Yet Another Price Target Hike After Waymo Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug

Okyo announced on Monday that it is now focused on advancing to a multiple-ascending-dose clinical trial, designed to enroll approximately 100 patients with neuropathic corneal pain across several U.S. clinical sites.

Equity

Okyo announced on Monday that it is now focused on advancing to a multiple-ascending-dose clinical trial, designed to enroll approximately 100 patients with neuropathic corneal pain across several U.S. clinical sites.


OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

Current Price	$1.72
Prev Close	$1.76
Open	$1.82
Dividend Yield	0.00%
50-Day Moving Average	$2.12
Beta	0.71
Avg. Volume	336,646.00
PE Ratio	-14.04

52-Week High	$3.35
52-Week Low	$1.03
Market Capitalization	$90.41M
EPS (Annual)	-$0.1192
Price to Book	-19.82
Revenue Per Employee	N/A

OKYO
Pharma Limited

Feed

News

Sentiment

Fundamentals

Info

Latest OKYO News

OKYOPharma Limited